Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04150497Phase 1Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Role: lead

NCT05607420Phase 1Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Role: lead

NCT03190278Phase 1Active Not Recruiting

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT04142619Phase 1Terminated

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Role: lead

NCT04106076Phase 1Withdrawn

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Role: lead

NCT03203369Phase 1Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Role: lead

All 6 trials loaded